CanSino Biologics Partners with Asymchem Laboratories to Innovate Biopharmaceutical Development
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into...
CRO / CMO / CDMO
VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions
VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...
Apeloa Pharmaceutical and ZhenGe Biotech Join Forces to Create Comprehensive ADC Platform
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has entered into a strategic partnership with domestic...
WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...
Novo Holdings to Acquire Catalent for $16.5 Billion in Strategic Move to Enhance Biopharmaceutical Capacity
Novo Holdings, the principal shareholder of Denmark’s Novo Nordisk (CPH: NOVO-B), has announced a definitive...
US Senate Puts Brakes on Bill Targeting China-Based CDMOs Amid Stock Market Reactions
A US Congress bill aimed at prohibiting US-funded entities from engaging with various China-based contract...
WuXi Biologics Achieves Full-Scale Manufacturing Milestone at Ireland Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
WuXi XDC Forecasts Over 100% Revenue Growth for 2023 on Strength of ADC Industry
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKEX: 2269) and WuXi STA,...
WuXi XDC Partners with Multitude Therapeutics and Signs MOU with Shanghai Huilian to Advance ADC Technologies
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Lonza Announces Factory Closures in the US and China Amid Global Network Optimization
Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...
China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies
A bipartisan bill introduced on January 26, 2024, by members of the US House Select...
WuXi Biologics Launches WuXiaADCC PLUS Platform for Non-Fucosylated Antibody Development
WuXi Biologics (HKG: 2269), a Contract Research, Development, and Manufacturing Organization (CRDMO) based in China,...
Jiuzhou Pharmaceutical Expands with $42 Million Investment in Japanese CRO Services
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to...
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...
Guangdong Aims to Boost Biomedicine Industry with Incentives and Strategic Development
The Guangdong Provincial Development and Reform Commission has unveiled an ambitious set of measures aimed...
WuXi Biologics’ Innovative Bispecific Platform WuXiBody Secures US Patent
WuXi Biologics (HKG: 2269), a leading China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has...
WuXi Biologics Partners with BioNTech to Develop Next-Gen Antibodies in $20 Million Deal
WuXi Biologics (HKG: 2269), a China-based Contract Research, Development, and Manufacturing Organization (CRDMO), has entered...
WuXi Biologics Expands Manufacturing Capacity to 36,000 Liters at Worcester Facility
WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...
Frontage Laboratories Expands European Footprint with Acquisition of Accelera’s DMPK Businesses
Frontage Laboratories Inc., (HKG: 1521), a Contract Research Organization (CRO) with operations in Pennsylvania, Suzhou,...
China Medical System Expands into Southeast Asia with Singapore Manufacturing Plant Lease
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that its joint venture, PharmaGend...